逸達生物科技 Foresee Pharmaceuticals Co., Ltd.
About Us
Company Profile
Business Model
Board of Directors
Management Team
Scientific Advisory Board
Others
R & D
Pipeline Overview
SIF Pipeline
FP-001:Prostate Cancer; Central Precocious Puberty
FP-014:Prostate Cancer
FP-016:Neurology/Psychiatry
FP-004:Opioid Dependence/Pain
FP-011:Breast Cancer
Other Research Projects
NCE Pipeline
FP-025:Asthma; COPD/ILD
FP-045: Fanconi Anemia; Pulmonary hypertension associated with interstitial lung disease (PH-ILD); Cardiovascular, Renal and Metabolism (CVRM); Peripheral artery disease (PAD)
FP-020: Sarcoidosis, Idiopathic pulmonary fibrosis (IPF), emphysema
FP-040: CNS Diseases
Media
Press Release
Media Library
Investors
Corporate Governance
Corporate Charters
Board of Directors
Others
Material Information
News & Events
Press Releases
Events & Presentations
Financial Information
Financial Results
Monthly Revenues
Sharholder Information
Annual General Meeting
Major Shareholders
FAQs
Investor Contacts
Others
Career
Benefits
Join Us
Contact Us
繁體中文
HOME
繁體中文
HOME
Media
Press Release
Keyword Search
Date
Title
2023-06-16
Foresee Pharmaceuticals Announces Poster Presentation and Participation at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs)
2023-04-17
Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development
2023-04-04
Foresee announced the Primary Endpoint Results of FP-025 in an Allergic Asthma Phase 2a Trial
2022-05-31
Foresee Pharmaceuticals Announces European Commission Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord Healthcare to Head the E.U. Commercialization
2022-04-04
Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI™ (Leuprolide) Injection Emulsion in the U.S. for the Treatment of Advanced Prostate Cancer in Adults
2022-02-23
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
2021-05-26
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord BioPharma to Head the U.S. Commercialization
2021-03-28
Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS
2021-03-04
Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States
2020-12-24
Foresee Pharmaceuticals Announces Completion of US$47 Million Financing
Total 29 ( 10 records per page )
Previous
Next
Go page
1
2
3